GSE135350 2 V 4 DEXAMETHASONE HUMAN UP (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE135350 2 V 4 DEXAMETHASONE HUMAN UP.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE135350 2 V 4 DEXAMETHASONE HUMAN UP.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE135350 2 V 4 DEXAMETHASONE HUMAN UP.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE135350 2 V 4 DEXAMETHASONE HUMAN UP.

Results found

Linked to

 

Label

Description

 

Gene

ribosomal protein S18

Gene

H2A clustered histone 11

Gene

ribosomal protein SA 2

Gene

protein phosphatase 2 regulatory subunit B''beta

Gene

RNA polymerase II subunit J3

Gene

leukocyte receptor cluster member 9

Gene

small integral membrane protein 44

Gene

long intergenic non-protein coding RNA 2798

Gene

glucagon like peptide 1 receptor

Gene

collapsin response mediator protein 1

  • Gene

    ribosomal protein S18


  • Gene

    H2A clustered histone 11


  • Gene

    ribosomal protein SA 2


  • Gene

    protein phosphatase 2 regulatory subunit B''beta


  • Gene

    RNA polymerase II subunit J3


  • Gene

    leukocyte receptor cluster member 9


  • Gene

    small integral membrane protein 44


  • Gene

    long intergenic non-protein coding RNA 2798


  • Gene

    glucagon like peptide 1 receptor


  • Gene

    collapsin response mediator protein 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.